JZJunping Zhang

Junping Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junping Zhang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Weidong Xiao

    Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA

    4 shared publications
  • Anh K. Lam

    Herman B Wells Center for Pediatric Research Indiana University Indianapolis Indiana USA

    2 shared publications
  • Dylan A. Frabutt

    Herman B Wells Center for Pediatric Research Indiana University Indianapolis Indiana USA

    2 shared publications
  • Matthew Chrzanowski

    Lewis Katz School of Medicine Temple University Philadelphia Pennsylvania USA

    2 shared publications
  • Patrick L. Mulcrone

    Herman B Wells Center for Pediatric Research Indiana University Indianapolis Indiana USA

    2 shared publications
  • Xiangping Yu

    Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA

    2 shared publications

Latest Publications

  • Bioinformatic Analysis of the Genetic Basis of Differential Adeno-Associated Virus Production Capability of 293 Variants

    by Christopher R. Herzog, Junping Zhang, Xiaomin Feng, Thao Thi Dang, Xiangping Yu, Jie Huang, Fang Fang, Hongyu Gao, Xuhong Yu, Yue Wang, et al.

    Human embryonic kidney 293 (HEK 293) cells are the main producer cell line for recombinant adeno-associated virus (rAAV) production. However, AAV vector yields among 293 clones vary considerably. To elucidate the biological basis for these differences, whole genomes of an adherent and a suspension 293 cell clone with high-yield rAAV were sequenced using nanopore technology. All 293 cell derivative lines showed a twofold copy number gain at the adenoviral integration site across, suggesting a genome duplication event. To our surprise, the two high-producer clones, despite having been separately developed, are biologically closely grouped together as compared to other commonly used 293 clones. Their genomes contain a similar adenoviral gene integration region, which likely leads to high expression of proteins that facilitate AAV replication and packaging. Thus, genome duplication in the adenovirus integration locus may be a key factor affecting AAV production yield.


  • Cryptic resolution sites in the vector plasmid lead to the heterogeneities in the rAAV vectors

    by Junping Zhang, Matthew Chrzanowski, Dylan A. Frabutt, Anh K. Lam, Patrick L. Mulcrone, Lei Li, Barbara A. Konkle, Carol H. Miao, Weidong Xiao

    Recombinant adeno‐associated virus (rAAV) vectors carry a cassette of interest retaining only the inverted terminal repeats (ITRs) from the wild‐type virus. Conventional rAAV production primarily uses a vector plasmid as well as helper genes essential for AAV replication and packaging. Nevertheless, plasmid backbone related contaminants have been a major source of vector heterogeneity. The mechanism driving the contamination phenomenon has yet to be elucidated. Here we identified cryptic resolution sites in the plasmid backbone as a key source for producing snapback genomes, which leads to the increase of vector genome heterogeneity in encapsidated virions. By using a single ITR plasmid as a model molecule and mapping subgenomic particles, we found that there exist a few typical DNA break hotspots in the vector DNA plasmid backbone, for example, on the ampicillin DNA element, called aberrant rescue sites. DNA around these specific breakage sites may assume some typical secondary structures. Similar to normal AAV vectors, plasmid DNA with a single ITR was able to rescue and replicate efficiently. These subgenomic DNA species significantly compete for trans factors required for rAAV rescue, replication, and packaging. The replication of single ITR contaminants during AAV production is independent of size. Packaging of these species is greatly affected by its size. A single ITR and a cryptic resolution site in the plasmid work synergistically, likely causing a source of plasmid backbone contamination.


  • Open Access

    Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes

    by Junping Zhang, Ping Guo, Xiangping Yu, Dylan A. Frabutt, Anh K. Lam, Patrick L. Mulcrone, Matthew Chrzanowski, Jenni Firrman, Derek Pouchnik, Nianli Sang, et al.


  • Open Access

    Genomic Designs of rAAVs Contribute to Pathological Changes in the Livers and Spleens of Mice

    by Patrick L. Mulcrone, Junping Zhang, P. Melanie Pride, Anh K. Lam, Dylan A. Frabutt, Susan M. Ball-Kell, Weidong Xiao

    Recombinant AAV (rAAV) gene therapy is being investigated as an effective therapy for several diseases including hemophilia B. Reports of liver tumor development in certain mouse models due to AAV treatment and genomic integration of the rAAV vector has raised concerns about the long-term safety and efficacy of this gene therapy. To investigate whether rAAV treatment causes cancer, we utilized two mouse models, inbred C57BL/6 and hemophilia B Balb/C mice (HemB), to test if injecting a high dose of various rAAV8 vectors containing or lacking hFIX transgene, a Poly-A sequence, or the CB or TTR promoter triggered liver fibrosis and/or cancer development over the course of the 6.5-month study. We observed no liver tumors in either mouse cohort regardless of rAAV treatment through ultrasound imaging, gross anatomical assessment at sacrifice, and histology. We did, however, detect differences in collagen deposition in C57BL/6 livers and HemB spleens of rAAV-injected mice. Pathology reports of the HemB mice revealed many pathological phenomena, including fibrosis and inflammation in the livers and spleens across different AAV-injected HemB mice. Mice from both cohorts injected with the TTR-hFIX vector demonstrated minimal adverse events. While not tumorigenic, high dose of rAAVs, especially those with incomplete genomes, can influence liver and spleen health negatively that could be problematic for cementing AAVs as a broad therapeutic option in the clinic.